Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

NCT05383209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonproliferative Diabetic Retinopathy

Interventions

DRUG: EYP-1901
OTHER: Sham IVT

Sponsor

EyePoint Pharmaceuticals, Inc.